InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Discover the full record of transactions filed by Partridge Andrew John, Directeur Exécutif Commercial. Officer active across 1 companies, notably Turning Point Therapeutics, Inc.. Cumulatively, 4 reports have been recorded. Total volume traded: €251k. The latest transaction was filed on 9 February 2022 — Cession. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations4 total
€7,024221 shares@ €31.78285.6% of flow
Common Stock
SEC:0001209191-22-008983·
€7,024221 shares@ €31.78282.8% of flow
Common Stock
SEC:0001209191-22-008983:0·
€118,3001,869 shares@ €63.295794.4% of flow
Common Stock
SEC:0001209191-21-046809·
€118,3001,869 shares@ €63.295747.2% of flow
Common Stock
SEC:0001209191-21-046809:0·
4 of 4 declarations
About Partridge Andrew John
Andrew John Partridge is the EVP & Chief Commercial Officer at Turning Point Therapeutics, Inc. He oversees the company's commercial initiatives and plays a key role in developing strategies to drive growth.
